Fulgent Genetics, Inc. (NASDAQ: FLGT) reported Q3 EPS of $0.31, $0.46 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $71.7 million versus the consensus estimate of $71.82 million.

GUIDANCE:

Fulgent Genetics, Inc. sees FY2024 revenue of ~$280 million, versus the consensus of $282.2 million.

For earnings history and earnings-related data on Fulgent Genetics, Inc. (FLGT) click here.